EQUITY RESEARCH / 2026 → 2029
Find a business worth researching. Understand what could drive growth, what could break the thesis, and how much success the entry price already assumes.
Research priorities reviewed 2026-09-23 · Editorial judgement, not a buy signal · Capital can be lost
SECTOR RESEARCH
Curated themes, not an industry index. Compare the business drivers first, then inspect individual companies and their entry valuations.
Compute, memory and optical links can benefit from larger AI deployments.
CRDO NBIS ALAB MU AMD AMAT ANET AVGO COHR AAOI
Qué seguir: Organic revenue; customer concentration; cash after capex; product margins.
Riesgo: AI spending is shared exposure: several tickers can depend on the same customers.
Electricity delivery and heat removal may constrain data-center expansion.
VRT ETN GEV
Qué seguir: Organic orders; backlog conversion; factory capacity; cash conversion.
Riesgo: Grid delays, capex cycles and high entry valuations.
Generation, components and fuel offer different exposure to nuclear investment.
BWXT CEG LEU
Qué seguir: Funded contracts; outages; fuel capacity; maintenance and expansion capex.
Riesgo: Permits, policy, project timing and financing; generators and fuel developers are not interchangeable.
Launch, communication and imaging require different paths to commercial scale.
RKLB ASTS PL RDW
Qué seguir: Operational launches; paid usage; backlog conversion; funded cash runway.
Riesgo: Launch failures, customer concentration and dilution.
Unmanned platforms and counter-drone systems may attract procurement.
AVAV KTOS
Qué seguir: Funded backlog; production deliveries; organic margins; cash collections.
Riesgo: Budget changes, program selection and contract execution losses.
Robotics, connected operations and testing can improve physical productivity.
SYM IOT TER
Qué seguir: Installation economics; recurring usage; customer concentration; segment margins.
Riesgo: Slow deployments and cyclical industrial or semiconductor budgets.
Diagnostics, surgical tools and drug discovery have distinct clinical and payment risks.
TEM HIMS RXRX ISRG NTRA GH TMDX
Qué seguir: Reimbursed volumes; clinical milestones; collections; cash runway.
Riesgo: Trial failure, reimbursement and regulation; do not value a drug pipeline like software.
Recurring tools support cloud operations, security and development.
NET CRWD DDOG
Qué seguir: Retention; consumption; recurring revenue; GAAP margins; diluted shares.
Riesgo: Competition, service incidents, stock compensation and entry multiples.
Advertising, cloud services and learning subscriptions can scale with engagement.
GOOGL DUOL APP
Qué seguir: Paid retention; advertiser returns; cash flow; organic growth.
Riesgo: Platform dependence, AI substitution, privacy rules and acquisition costs.
Useful technical performance must turn into repeat paid commercial demand.
IONQ QBTS RGTI QUBT
Qué seguir: External orders; organic revenue; cash burn; reproducible technical milestones.
Riesgo: Technical uncertainty, lumpy sales, acquisitions and dilution.
Higher energy density matters only if manufacturing becomes commercially viable.
ENVX
Qué seguir: Qualified customers; manufacturing yield; unit cost; funded capacity.
Riesgo: Qualification delays, yield failures and financing.
A broader customer relationship can support fee revenue and operating scale.
SOFI
Qué seguir: Credit losses; capital adequacy; deposit costs; normalized earnings.
Riesgo: Credit cycles and regulation; software sales multiples are inappropriate.
Coverage counts refer to this entire list and its current snapshots. Positive margin counts use only issuers with a known trailing-four-quarter net margin; a dash means unavailable. Different fiscal periods and business models are not directly comparable.
| Empresa | Prioridad de investigación | Riesgo | ¿Por qué investigarlo? | Observaciones con fecha |
|---|---|---|---|---|
| CRDOCredo TechnologyAI connectivityCrecimiento comercial | Prioridad de investigación★★★★☆4 / 5 | RiesgoAlto4 / 5 | Higher bandwidth creates demand for efficient links inside AI clusters. Tesis, riesgos y fuentesQué debe salir bienBroader customer adoption and sustained margins as connectivity speeds rise. Qué rompería la tesisCustomer concentration, competing optical designs or margin compression. Antes de evaluar el precioCompare forward earnings and free cash flow with customer concentration. Escenario de retorno excepcional10× needs sustained expansion well beyond the current customer base; valuation is unverified. Company newsroom lists FY2027 Q1 results and optical connectivity updates. Fuente de la empresa ↗ Datos de la empresa → |
$150.99Stored close · 2026-10-30-50.1%From 252-session closing peak
Cambio en 63 sesiones -30.8%Cambio en 252 sesiones -12.0%
Crecimiento de ingresos 114.7%Margen neto 33.8%ROE 19.7%Aceleración de EPS —Período de reporte 2026-08-01SEC · 2026-09-02 ↗
|
| NBISNebiusAI cloudCrecimiento comercial | Prioridad de investigación★★★★☆4 / 5 | RiesgoExtremo5 / 5 | AI compute demand may support a larger specialist cloud business. Tesis, riesgos y fuentesQué debe salir bienCommission capacity, fill it with paying customers and improve cash returns. Qué rompería la tesisPower delays, underutilized GPUs, capex funding and shareholder dilution. Antes de evaluar el precioValue cash flow after capex and debt; contracted demand is not earned revenue. Escenario de retorno excepcional10× is an exceptional execution and funding scenario, not a base case. Q2 2026 results published August 12; AI cloud business and investment exposure disclosed. Fuente de la empresa ↗ Métricas de la SEC no cubiertas |
—Cierre reciente no disponible Métricas de la SEC no cubiertas |
| RKLBRocket LabSpace systems & launchCrecimiento comercial | Prioridad de investigación★★★★☆4 / 5 | RiesgoExtremo5 / 5 | Launch services and spacecraft systems can serve growing commercial and defense demand. Tesis, riesgos y fuentesQué debe salir bienConvert contracted backlog to cash and deliver the Neutron program. Qué rompería la tesisLaunch failures, development delays, acquisition integration and dilution. Antes de evaluar el precioSeparate organic sales, acquisition effects, capex and fully diluted shares. Escenario de retorno excepcional10× requires much more than a successful launch; funding and entry valuation matter. Q2 2026 release reports growing revenue/backlog and an announced Iridium acquisition. Fuente de la empresa ↗ Datos de la empresa → |
$54.73Stored close · 2026-10-30-63.6%From 252-session closing peak
Cambio en 63 sesiones -22.3%Cambio en 252 sesiones -17.3%
Crecimiento de ingresos 62.0%Margen neto -21.5%ROE -4.7%Aceleración de EPS —Período de reporte 2026-06-30SEC · 2026-08-10 ↗
|
| ALABAstera LabsAI connectivityCrecimiento comercial | Prioridad de investigación★★★★☆4 / 5 | RiesgoAlto4 / 5 | More complex AI systems need additional connectivity and switching products. Tesis, riesgos y fuentesQué debe salir bienScale Scorpio deployments and diversify product and customer revenue. Qué rompería la tesisCustomer concentration, competitive standards and a high entry valuation. Antes de evaluar el precioCheck revenue multiple, cash generation and stock-based compensation. Escenario de retorno excepcional10× needs product expansion plus a defensible entry multiple; growth alone is insufficient. Q2 2026 release discusses Scorpio deployment and expansion of connectivity products. Fuente de la empresa ↗ Datos de la empresa → |
$258.70Stored close · 2026-10-30-46.4%From 252-session closing peak
Cambio en 63 sesiones -19.4%Cambio en 252 sesiones +49.0%
Crecimiento de ingresos 104.5%Margen neto 30.7%ROE 21.4%Aceleración de EPS 41.8 ppPeríodo de reporte 2026-06-30SEC · 2026-08-05 ↗
|
| VRTVertivPower & coolingCrecimiento comercial | Prioridad de investigación★★★★☆4 / 5 | RiesgoAlto4 / 5 | AI capacity needs power management and heat removal as well as chips. Tesis, riesgos y fuentesQué debe salir bienDeliver liquid cooling and power capacity with healthy cash conversion. Qué rompería la tesisHyperscaler capex slowdown, manufacturing bottlenecks and pricing pressure. Antes de evaluar el precioCheck organic growth, working capital and free cash flow after capacity investment. Escenario de retorno excepcional10× would require exceptional expansion from an already established business; entry valuation is unverified. July 29, 2026 release: Q2 sales rose 24%, including 18% organic growth. Fuente de la empresa ↗ Datos de la empresa → |
$232.50Stored close · 2026-10-30-38.2%From 252-session closing peak
Cambio en 63 sesiones -11.6%Cambio en 252 sesiones +16.7%
Crecimiento de ingresos 61.2%Margen neto 16.0%ROE 38.1%Aceleración de EPS 38.2 ppPeríodo de reporte 2026-09-30SEC · 2026-10-28 ↗
|
| ETNEatonElectrical equipmentEmpresas de comparación | Prioridad de investigación★★★★☆4 / 5 | RiesgoSustancial3 / 5 | Grid expansion and data centers require electrical distribution and protection equipment. Tesis, riesgos y fuentesQué debe salir bienConvert electrical backlog into deliveries while preserving margins. Qué rompería la tesisProject delays, acquisition integration and a premium entry valuation. Antes de evaluar el precioSeparate organic sales from acquisitions; compare cash earnings with normalized capex. Escenario de retorno excepcionalEstablished industry comparison; 10× over 2–3 years is not a base case. Q2 2026 release: sales rose 21%, comprising 14% organic growth and 7% from acquisitions. Fuente de la empresa ↗ Datos de la empresa → |
$366.07Stored close · 2026-11-02-20.4%From 252-session closing peak
Cambio en 63 sesiones -17.7%Cambio en 252 sesiones -4.4%
Crecimiento de ingresos 21.4%Margen neto 12.8%ROE 18.9%Aceleración de EPS -6.5 ppPeríodo de reporte 2026-06-30SEC · 2026-07-31 ↗
|
| GEVGE VernovaGrid & generation equipmentEmpresas de comparación | Prioridad de investigación★★★★☆4 / 5 | RiesgoAlto4 / 5 | Grid equipment, power generation and services address growing electricity requirements. Tesis, riesgos y fuentesQué debe salir bienConvert Power and Electrification orders into profitable deliveries. Qué rompería la tesisLong delivery cycles, wind losses, warranty costs and execution risk. Antes de evaluar el precioSeparate equipment and service economics; orders and customer advances are not earnings. Escenario de retorno excepcionalIndustry comparison; a large backlog does not establish a 10× share-price opportunity. July 22, 2026 release: Q2 revenue rose 22%, or 12% organically, led by Power and Electrification. Fuente de la empresa ↗ Datos de la empresa → |
$857.87Stored close · 2026-10-30-27.0%From 252-session closing peak
Cambio en 63 sesiones -14.8%Cambio en 252 sesiones +48.4%
Crecimiento de ingresos 26.8%Margen neto 23.5%ROE 91.1%Aceleración de EPS 160.5 ppPeríodo de reporte 2026-09-30SEC · 2026-10-28 ↗
|
| BWXTBWX TechnologiesNuclear componentsCrecimiento comercial | Prioridad de investigación★★★★☆4 / 5 | RiesgoAlto4 / 5 | Nuclear components and services participate in defense and commercial reactor investment. Tesis, riesgos y fuentesQué debe salir bienDeliver funded programs and expand manufacturing with disciplined cash returns. Qué rompería la tesisGovernment concentration, project overruns and acquisition integration. Antes de evaluar el precioInspect funded backlog, contract margins and free cash flow after factory expansion. Escenario de retorno excepcional10× needs exceptional per-share growth; nuclear exposure alone does not support it. August 3, 2026 release reports Q2 revenue of $901.6m and net income of $89.1m. Fuente de la empresa ↗ Datos de la empresa → |
$130.70Stored close · 2026-10-30-45.2%From 252-session closing peak
Cambio en 63 sesiones -24.8%Cambio en 252 sesiones -38.8%
Crecimiento de ingresos 18.0%Margen neto 10.1%ROE 26.6%Aceleración de EPS -6.6 ppPeríodo de reporte 2026-06-30SEC · 2026-08-05 ↗
|
| ANETArista NetworksData-center networkingEmpresas de comparación | Prioridad de investigación★★★★☆4 / 5 | RiesgoAlto4 / 5 | Larger AI clusters require high-bandwidth Ethernet networking and software. Tesis, riesgos y fuentesQué debe salir bienConvert AI networking deployments into sustained sales and customer diversification. Qué rompería la tesisHyperscaler concentration, competing architectures and valuation compression. Antes de evaluar el precioCheck customer acceptance terms, inventory and cash conversion alongside earnings. Escenario de retorno excepcionalEstablished networking comparison; no supported 10× forecast from demand growth alone. Investor materials link Q2 2026 results and cloud/AI networking presentations. Fuente de la empresa ↗ Datos de la empresa → |
$168.86Stored close · 2026-10-30-22.1%From 252-session closing peak
Cambio en 63 sesiones -8.7%Cambio en 252 sesiones +4.2%
Crecimiento de ingresos 37.7%Margen neto 38.4%ROE 27.3%Aceleración de EPS 10.7 ppPeríodo de reporte 2026-06-30SEC · 2026-08-05 ↗
|
| ASTSAST SpaceMobileSatellite connectivityTecnología de vanguardia | Prioridad de investigación★★★☆☆3 / 5 | RiesgoExtremo5 / 5 | Direct-to-phone satellite broadband could open a new connectivity market. Tesis, riesgos y fuentesQué debe salir bienLaunch and commission satellites, obtain approvals and convert coverage into paid service. Qué rompería la tesisLaunch or deployment failure, spectrum limits, funding needs and dilution. Antes de evaluar el precioModel funded satellite deployment and paying usage, not only addressable market. Escenario de retorno excepcional10× depends on network economics and funding; technical success alone is insufficient. Investor page describes the direct-to-cell network and links Q2 2026 filings. Fuente de la empresa ↗ Datos de la empresa → |
$40.97Stored close · 2026-10-30-69.2%From 252-session closing peak
Cambio en 63 sesiones -35.5%Cambio en 252 sesiones -48.8%
Crecimiento de ingresos —Margen neto —ROE -25.8%Aceleración de EPS —Período de reporte 2026-06-30SEC · 2026-08-10 ↗
|
| PLPlanet LabsEarth observationCrecimiento comercial | Prioridad de investigación★★★☆☆3 / 5 | RiesgoAlto4 / 5 | Repeated Earth imagery can support government and commercial data subscriptions. Tesis, riesgos y fuentesQué debe salir bienRenew contracts, expand analytics usage and convert bookings into cash. Qué rompería la tesisGovernment budget concentration, competition and satellite replacement costs. Antes de evaluar el precioCheck recurring revenue quality, gross margin and cash flow after constellation costs. Escenario de retorno excepcional10× needs durable cash-generating scale; no probability is assigned. Company investor overview; current valuation has not been validated. Fuente de la empresa ↗ Datos de la empresa → |
$13.47Stored close · 2026-10-30-73.8%From 252-session closing peak
Cambio en 63 sesiones -37.4%Cambio en 252 sesiones +4.4%
Crecimiento de ingresos 58.1%Margen neto -95.1%ROE -63.8%Aceleración de EPS —Período de reporte 2026-07-31SEC · 2026-09-03 ↗
|
| RDWRedwireSpace & defenseCrecimiento comercial | Prioridad de investigación★★★☆☆3 / 5 | RiesgoExtremo5 / 5 | Space infrastructure and defense platforms can benefit from program expansion. Tesis, riesgos y fuentesQué debe salir bienExecute contracts, integrate acquired operations and convert backlog into cash. Qué rompería la tesisProgram delays, acquisition integration, debt and contract execution losses. Antes de evaluar el precioCheck organic growth, debt, working capital and cash conversion. Escenario de retorno excepcional10× requires profitable expansion without excessive dilution or leverage. Investor page describes space/defense operations and links Q2 2026 results. Fuente de la empresa ↗ Datos de la empresa → |
$8.39Stored close · 2026-10-30-67.6%From 252-session closing peak
Cambio en 63 sesiones -13.0%Cambio en 252 sesiones +6.9%
Crecimiento de ingresos 89.6%Margen neto -57.3%ROE -15.0%Aceleración de EPS —Período de reporte 2026-06-30SEC · 2026-08-06 ↗
|
| TEMTempus AIHealthcare dataCrecimiento comercial | Prioridad de investigación★★★☆☆3 / 5 | RiesgoAlto4 / 5 | Diagnostics and clinical data may support a growing precision-medicine business. Tesis, riesgos y fuentesQué debe salir bienGrow paid testing and data licensing with improving unit economics. Qué rompería la tesisReimbursement, privacy obligations, competition and integration costs. Antes de evaluar el precioSeparate diagnostics margins from data licensing and exclude acquisition-only growth. Escenario de retorno excepcional10× requires durable per-share economics; the AI label is not a valuation model. Investor overview describes diagnostics and clinical-data products. Fuente de la empresa ↗ Datos de la empresa → |
$72.22Stored close · 2026-10-30-19.6%From 252-session closing peak
Cambio en 63 sesiones +56.8%Cambio en 252 sesiones -18.7%
Crecimiento de ingresos 21.6%Margen neto -17.8%ROE -57.2%Aceleración de EPS —Período de reporte 2026-06-30SEC · 2026-07-30 ↗
|
| HIMSHims & HersDigital healthCrecimiento comercial | Prioridad de investigación★★★☆☆3 / 5 | RiesgoExtremo5 / 5 | Digital distribution can broaden access to repeat-purchase healthcare services. Tesis, riesgos y fuentesQué debe salir bienImprove retention and expand compliant product offerings with profitable acquisition costs. Qué rompería la tesisProduct regulation, supplier access, customer acquisition costs and churn. Antes de evaluar el precioCheck sustainable gross profit, retention and cash flow by product line. Escenario de retorno excepcional10× would require durable expansion; a temporary product surge is insufficient. Company investor overview; SEC metrics are shown separately when covered. Fuente de la empresa ↗ Datos de la empresa → |
$27.68Stored close · 2026-10-30-39.1%From 252-session closing peak
Cambio en 63 sesiones -10.2%Cambio en 252 sesiones -40.6%
Crecimiento de ingresos 38.2%Margen neto -5.5%ROE -43.8%Aceleración de EPS -17.6 ppPeríodo de reporte 2026-06-30SEC · 2026-08-10 ↗
|
| IONQIonQQuantum computingTecnología de vanguardia | Prioridad de investigación★★★☆☆3 / 5 | RiesgoExtremo5 / 5 | Useful quantum systems could create demand for computing and related infrastructure. Tesis, riesgos y fuentesQué debe salir bienDemonstrate paid deployments, repeat orders and useful technical performance. Qué rompería la tesisCommercial utility may arrive late; cash burn, acquisitions and valuation can dominate. Antes de evaluar el precioSeparate organic revenue from acquired businesses; inspect cash burn and diluted shares. Escenario de retorno excepcional10× is a tail scenario dependent on commercial adoption and entry valuation. Q2 2026 release discloses commercial deployments, losses and the SkyWater acquisition. Fuente de la empresa ↗ Datos de la empresa → |
$30.04Stored close · 2026-10-30-58.3%From 252-session closing peak
Cambio en 63 sesiones -22.7%Cambio en 252 sesiones -50.8%
Crecimiento de ingresos 286.8%Margen neto -553.3%ROE -41.0%Aceleración de EPS —Período de reporte 2026-06-30SEC · 2026-08-10 ↗
|
| SOFISoFi TechnologiesFinancial servicesEmpresas de comparación | Prioridad de investigación★★★☆☆3 / 5 | RiesgoAlto4 / 5 | Broader financial services may increase customer revenue and operating scale. Tesis, riesgos y fuentesQué debe salir bienGrow durable fee income while controlling credit losses and acquisition costs. Qué rompería la tesisCredit deterioration, funding costs, regulation and valuation compression. Antes de evaluar el precioCheck normalized earnings, credit losses, capital and tangible book value. Escenario de retorno excepcionalIncluded as a comparison business; 10×/100× is not an underwriting assumption. Company investor overview; current valuation is unverified in this screen. Fuente de la empresa ↗ Datos de la empresa → |
$16.76Stored close · 2026-10-30-48.0%From 252-session closing peak
Cambio en 63 sesiones -7.0%Cambio en 252 sesiones -45.8%
Crecimiento de ingresos 1.1%Margen neto 104.3%ROE 5.7%Aceleración de EPS -50.0 ppPeríodo de reporte 2026-06-30SEC · 2026-08-06 ↗
|
| MUMicronMemory semiconductorsEmpresas de comparación | Prioridad de investigación★★★☆☆3 / 5 | RiesgoAlto4 / 5 | AI systems require additional memory capacity and bandwidth. Tesis, riesgos y fuentesQué debe salir bienHBM execution and sustained returns on capacity investment through the cycle. Qué rompería la tesisMemory oversupply, cyclical pricing, capex and export restrictions. Antes de evaluar el precioUse mid-cycle earnings and cash flow; peak-cycle P/E can look misleadingly cheap. Escenario de retorno excepcionalCycle comparison, not a validated 10× or 100× candidate. Investor materials discuss AI memory demand, HBM and capacity investment. Fuente de la empresa ↗ Datos de la empresa → |
$833.59Stored close · 2026-11-02-31.3%From 252-session closing peak
Cambio en 63 sesiones -6.6%Cambio en 252 sesiones +272.1%
Crecimiento de ingresos 379.3%Margen neto 63.8%ROE 61.4%Aceleración de EPS 612.4 ppPeríodo de reporte 2026-09-03SEC · 2026-10-09 ↗
|
| AMDAdvanced Micro DevicesCompute semiconductorsEmpresas de comparación | Prioridad de investigación★★★☆☆3 / 5 | RiesgoAlto4 / 5 | Server processors and accelerators can participate in AI infrastructure spending. Tesis, riesgos y fuentesQué debe salir bienAccelerator adoption, software execution and profitable server share growth. Qué rompería la tesisStrong competition, customer concentration, supply constraints and export rules. Antes de evaluar el precioCompare earnings and free cash flow with accelerator margins and dilution. Escenario de retorno excepcionalComparison company; being smaller than a competitor does not establish 10× upside. Investor materials include Q2 2026 results and AI infrastructure partnerships. Fuente de la empresa ↗ Datos de la empresa → |
$466.84Stored close · 2026-11-02-28.1%From 252-session closing peak
Cambio en 63 sesiones -10.0%Cambio en 252 sesiones +83.2%
Crecimiento de ingresos 50.1%Margen neto 15.6%ROE 9.6%Aceleración de EPS 64.6 ppPeríodo de reporte 2026-06-27SEC · 2026-08-05 ↗
|
| AMATApplied MaterialsChipmaking equipmentEmpresas de comparación | Prioridad de investigación★★★☆☆3 / 5 | RiesgoSustancial3 / 5 | More complex chips can increase demand for process equipment and services. Tesis, riesgos y fuentesQué debe salir bienTechnology transitions and sustained customer investment. Qué rompería la tesisSemiconductor capex cycles, export restrictions and customer concentration. Antes de evaluar el precioCompare mid-cycle cash earnings and services durability with the entry price. Escenario de retorno excepcionalEquipment-cycle comparison; 10×/100× is not an investment premise. Company investor relations; no claim that the current price is cheap. Fuente de la empresa ↗ Datos de la empresa → |
$374.53Stored close · 2026-11-02-48.2%From 252-session closing peak
Cambio en 63 sesiones -31.5%Cambio en 252 sesiones +61.1%
Crecimiento de ingresos 24.8%Margen neto 30.1%ROE 36.2%Aceleración de EPS 9.3 ppPeríodo de reporte 2026-07-26SEC · 2026-08-20 ↗
|
| GOOGLAlphabetCloud & digital platformsEmpresas de comparación | Prioridad de investigación★★★☆☆3 / 5 | RiesgoSustancial3 / 5 | Cloud growth and AI products may add to an established digital business. Tesis, riesgos y fuentesQué debe salir bienMonetize AI while sustaining search economics and returns on capex. Qué rompería la tesisSearch disruption, antitrust remedies and heavy infrastructure spending. Antes de evaluar el precioCheck free cash flow after AI capex and the durability of search margins. Escenario de retorno excepcionalEstablished-business comparison; no supported 10×/100× thesis over 2–3 years. Alphabet investor materials; cheapness requires a verified entry valuation. Fuente de la empresa ↗ Métricas de la SEC no cubiertas |
—Cierre reciente no disponible Métricas de la SEC no cubiertas |
| CEGConstellation EnergyPower generationEmpresas de comparación | Prioridad de investigación★★★☆☆3 / 5 | RiesgoAlto4 / 5 | Existing nuclear generation can supply reliable electricity to growing loads. Tesis, riesgos y fuentesQué debe salir bienSign attractive power contracts and operate the generation fleet reliably. Qué rompería la tesisOutages, power-price changes, integration costs and regulatory intervention. Antes de evaluar el precioModel contracted versus merchant power prices, maintenance capex and debt. Escenario de retorno excepcionalEstablished generator comparison; growth in electricity demand is not a 10× forecast. Investor materials describe a diversified generation fleet, nuclear operations and the Calpine transaction. Fuente de la empresa ↗ Datos de la empresa → |
$262.38Stored close · 2026-10-30-31.4%From 252-session closing peak
Cambio en 63 sesiones -4.1%Cambio en 252 sesiones -34.6%
Crecimiento de ingresos 13.2%Margen neto 14.0%ROE 10.8%Aceleración de EPS -1128.4 ppPeríodo de reporte 2026-06-30SEC · 2026-08-06 ↗
|
| AVGOBroadcomCustom compute & networkingEmpresas de comparación | Prioridad de investigación★★★☆☆3 / 5 | RiesgoAlto4 / 5 | Custom accelerators and networking may capture a share of AI infrastructure spending. Tesis, riesgos y fuentesQué debe salir bienScale custom compute programs and maintain recurring infrastructure software economics. Qué rompería la tesisCustomer concentration, leverage, program delays and multiple compression. Antes de evaluar el precioSeparate semiconductor cyclicality from software cash flow; include debt and dilution. Escenario de retorno excepcionalLarge established-business comparison, not a validated 10× or 100× candidate. Company investor materials cover semiconductor solutions and infrastructure software. Fuente de la empresa ↗ Datos de la empresa → |
$322.23Stored close · 2026-11-02-33.1%From 252-session closing peak
Cambio en 63 sesiones -22.9%Cambio en 252 sesiones -14.4%
Crecimiento de ingresos 85.5%Margen neto —ROE —Aceleración de EPS 129.9 ppPeríodo de reporte 2026-08-02SEC · 2026-09-10 ↗
|
| COHRCoherentOptical componentsCrecimiento comercial | Prioridad de investigación★★★☆☆3 / 5 | RiesgoAlto4 / 5 | Faster data-center links increase the need for optical transceivers and photonics. Tesis, riesgos y fuentesQué debe salir bienExpand high-speed optical capacity with sustained yields and margins. Qué rompería la tesisOptical pricing pressure, customer concentration, debt and manufacturing execution. Antes de evaluar el precioCheck organic sales, leverage and cash flow after capacity spending. Escenario de retorno excepcional10× needs durable per-share cash growth and a defensible entry valuation. August 12, 2026 release: fiscal Q4 revenue of $2.05bn, up 34% year on year. Fuente de la empresa ↗ Datos de la empresa → |
$210.32Stored close · 2026-10-30-50.7%From 252-session closing peak
Cambio en 63 sesiones -27.0%Cambio en 252 sesiones +52.3%
Crecimiento de ingresos 33.7%Margen neto 11.3%ROE 7.4%Aceleración de EPS —Período de reporte 2026-06-30SEC · 2026-08-14 ↗
|
| AAOIApplied OptoelectronicsOptical transceiversCrecimiento comercial | Prioridad de investigación★★★☆☆3 / 5 | RiesgoExtremo5 / 5 | Optical links can benefit from increasing data-center bandwidth requirements. Tesis, riesgos y fuentesQué debe salir bienWin repeat high-speed transceiver orders and improve production yields. Qué rompería la tesisCustomer concentration, product qualification delays, losses and funding needs. Antes de evaluar el precioCheck sustainable gross profit, capex and cash runway instead of extrapolating a small base. Escenario de retorno excepcionalA speculative manufacturing scale-up; volume growth may not translate into per-share value. Company investor materials describe fiber-optic access and data-center products. Fuente de la empresa ↗ Datos de la empresa → |
$69.05Stored close · 2026-10-30-69.0%From 252-session closing peak
Cambio en 63 sesiones -37.3%Cambio en 252 sesiones +94.6%
Crecimiento de ingresos 86.4%Margen neto -9.6%ROE -3.4%Aceleración de EPS —Período de reporte 2026-06-30SEC · 2026-08-06 ↗
|
| SYMSymboticWarehouse automationCrecimiento comercial | Prioridad de investigación★★★☆☆3 / 5 | RiesgoExtremo5 / 5 | Warehouse automation can reduce handling costs and increase throughput. Tesis, riesgos y fuentesQué debe salir bienInstall systems on time and grow profitable recurring service revenue. Qué rompería la tesisCustomer concentration, installation delays and cost overruns. Antes de evaluar el precioCheck backlog cancellation terms, deployment margins and cash advances. Escenario de retorno excepcional10× requires successful deployment at scale and attractive economics for shareholders. Company investor materials describe robotic warehouse systems and software. Fuente de la empresa ↗ Datos de la empresa → |
$37.93Stored close · 2026-10-30-56.6%From 252-session closing peak
Cambio en 63 sesiones -17.3%Cambio en 252 sesiones -51.2%
Crecimiento de ingresos 21.7%Margen neto 0.5%ROE 1.8%Aceleración de EPS —Período de reporte 2026-06-27SEC · 2026-08-05 ↗
|
| IOTSamsaraConnected operationsCrecimiento comercial | Prioridad de investigación★★★☆☆3 / 5 | RiesgoAlto4 / 5 | Fleet and industrial data can support recurring software for physical operations. Tesis, riesgos y fuentesQué debe salir bienExpand paid deployments while sustaining retention and sales efficiency. Qué rompería la tesisCompetition, hardware costs, customer budgets and share-based compensation. Antes de evaluar el precioCompare recurring revenue growth, retention and free cash flow after dilution. Escenario de retorno excepcional10× is exceptional; recurring revenue alone does not justify any entry multiple. Company investor overview describes its Connected Operations platform. Fuente de la empresa ↗ Datos de la empresa → |
$42.07Stored close · 2026-10-30-7.0%From 252-session closing peak
Cambio en 63 sesiones +13.3%Cambio en 252 sesiones +7.0%
Crecimiento de ingresos 29.9%Margen neto 4.9%ROE 5.7%Aceleración de EPS —Período de reporte 2026-08-01SEC · 2026-09-08 ↗
|
| TERTeradyneTest equipment & roboticsEmpresas de comparación | Prioridad de investigación★★★☆☆3 / 5 | RiesgoAlto4 / 5 | More complex chips need testing, while industrial automation offers another demand channel. Tesis, riesgos y fuentesQué debe salir bienConvert semiconductor test demand and improve robotics economics. Qué rompería la tesisSemiconductor cycles, customer concentration and uneven robot adoption. Antes de evaluar el precioUse segment-level and mid-cycle earnings; do not treat test revenue as robotics revenue. Escenario de retorno excepcionalIndustrial comparison; no supported 10×/100× premise. Company investor materials cover semiconductor test and robotics businesses. Fuente de la empresa ↗ Datos de la empresa → |
$274.37Stored close · 2026-10-30-43.3%From 252-session closing peak
Cambio en 63 sesiones -25.0%Cambio en 252 sesiones +57.7%
Crecimiento de ingresos 103.9%Margen neto 25.8%ROE 33.5%Aceleración de EPS 71.0 ppPeríodo de reporte 2026-06-28SEC · 2026-07-31 ↗
|
| AVAVAeroVironmentAutonomous defense systemsCrecimiento comercial | Prioridad de investigación★★★☆☆3 / 5 | RiesgoAlto4 / 5 | Demand for unmanned systems and counter-drone capabilities may support defense programs. Tesis, riesgos y fuentesQué debe salir bienScale funded production and convert contracts into cash. Qué rompería la tesisProcurement delays, contract losses, integration risk and export restrictions. Antes de evaluar el precioSeparate organic growth from acquired operations and inspect funded backlog. Escenario de retorno excepcional10× needs exceptional program expansion and cash generation; awards are not revenue. Investor page links fiscal Q1 2027 results dated September 9, 2026 and describes autonomous and counter-UAS systems. Fuente de la empresa ↗ Datos de la empresa → |
$126.11Stored close · 2026-10-30-67.9%From 252-session closing peak
Cambio en 63 sesiones -20.8%Cambio en 252 sesiones -66.9%
Crecimiento de ingresos 5.7%Margen neto —ROE —Aceleración de EPS —Período de reporte 2026-08-01SEC · 2026-09-10 ↗
|
| KTOSKratos DefenseDefense platforms & propulsionCrecimiento comercial | Prioridad de investigación★★★☆☆3 / 5 | RiesgoExtremo5 / 5 | Affordable unmanned platforms, propulsion and space systems may win larger programs. Tesis, riesgos y fuentesQué debe salir bienMove development projects into funded repeat production. Qué rompería la tesisPrograms may not scale; procurement timing, development spending and dilution. Antes de evaluar el precioDistinguish prototypes and contract ceilings from funded production and earned revenue. Escenario de retorno excepcional10× depends on program selection, funding and scalable margins. Company materials describe unmanned systems, propulsion, hypersonics and space capabilities. Fuente de la empresa ↗ Datos de la empresa → |
$41.09Stored close · 2026-10-30-68.6%From 252-session closing peak
Cambio en 63 sesiones -16.5%Cambio en 252 sesiones -55.0%
Crecimiento de ingresos 30.5%Margen neto 2.0%ROE 0.9%Aceleración de EPS -133.3 ppPeríodo de reporte 2026-06-28SEC · 2026-08-04 ↗
|
| ISRGIntuitive SurgicalSurgical roboticsEmpresas de comparación | Prioridad de investigación★★★☆☆3 / 5 | RiesgoSustancial3 / 5 | An installed surgical robot base can support recurring instruments and service demand. Tesis, riesgos y fuentesQué debe salir bienGrow procedures and system utilization with healthy recurring economics. Qué rompería la tesisHospital budgets, competition, regulatory issues and high entry expectations. Antes de evaluar el precioTrack procedure growth and recurring gross profit; distinguish placements from utilization. Escenario de retorno excepcionalEstablished medical technology comparison, not a validated 10× candidate. Company investor materials describe robotic-assisted surgery systems and recurring products. Fuente de la empresa ↗ Datos de la empresa → |
$436.87Stored close · 2026-11-02-26.3%From 252-session closing peak
Cambio en 63 sesiones +18.6%Cambio en 252 sesiones -17.6%
Crecimiento de ingresos 21.7%Margen neto 25.5%ROE 18.5%Aceleración de EPS -50.1 ppPeríodo de reporte 2026-09-30SEC · 2026-10-21 ↗
|
| NTRANateraMolecular diagnosticsCrecimiento comercial | Prioridad de investigación★★★☆☆3 / 5 | RiesgoAlto4 / 5 | Clinical adoption of molecular testing may expand monitoring and diagnostic demand. Tesis, riesgos y fuentesQué debe salir bienGrow reimbursed tests with improving cash collections and unit economics. Qué rompería la tesisReimbursement, clinical evidence, litigation and funding requirements. Antes de evaluar el precioCompare recognized revenue with collections, test mix and cash burn. Escenario de retorno excepcional10× requires clinical adoption and durable reimbursement economics. Investor materials describe cell-free DNA testing across clinical applications. Fuente de la empresa ↗ Datos de la empresa → |
$414.30Stored close · 2026-10-30-5.0%From 252-session closing peak
Cambio en 63 sesiones +53.2%Cambio en 252 sesiones +114.9%
Crecimiento de ingresos 37.7%Margen neto -7.1%ROE -10.6%Aceleración de EPS —Período de reporte 2026-06-30SEC · 2026-08-07 ↗
|
| GHGuardant HealthOncology diagnosticsCrecimiento comercial | Prioridad de investigación★★★☆☆3 / 5 | RiesgoExtremo5 / 5 | Blood-based oncology testing and screening may broaden the addressable patient population. Tesis, riesgos y fuentesQué debe salir bienGrow reimbursed testing and reduce cash consumption as volumes scale. Qué rompería la tesisReimbursement, screening adoption, competition and continued losses. Antes de evaluar el precioInspect test-level economics, collections and funded runway; revenue growth alone is insufficient. Escenario de retorno excepcional10× needs profitable adoption at scale; clinical usefulness is not proof of shareholder returns. July 30, 2026 release: Q2 revenue of $335.0m, up 44%, with continuing losses. Fuente de la empresa ↗ Datos de la empresa → |
$178.80Stored close · 2026-10-30-4.5%From 252-session closing peak
Cambio en 63 sesiones +12.6%Cambio en 252 sesiones +147.4%
Crecimiento de ingresos 44.3%Margen neto -38.3%ROE —Aceleración de EPS —Período de reporte 2026-06-30SEC · 2026-07-30 ↗
|
| TMDXTransMedicsOrgan transplant technologyCrecimiento comercial | Prioridad de investigación★★★☆☆3 / 5 | RiesgoAlto4 / 5 | Organ preservation and transplant logistics may increase the use of available donor organs. Tesis, riesgos y fuentesQué debe salir bienExpand transplant volumes and logistics efficiency with sustainable margins. Qué rompería la tesisClinical or regulatory setbacks, logistics costs and hospital adoption. Antes de evaluar el precioSeparate technology and logistics economics; include aircraft and other capital needs. Escenario de retorno excepcional10× needs repeatable clinical adoption and profitable capital-efficient expansion. Company investor materials describe the Organ Care System and transplant logistics. Fuente de la empresa ↗ Datos de la empresa → |
$65.99Stored close · 2026-10-30-56.1%From 252-session closing peak
Cambio en 63 sesiones -19.1%Cambio en 252 sesiones -50.9%
Crecimiento de ingresos 20.7%Margen neto 22.7%ROE 29.3%Aceleración de EPS 16.0 ppPeríodo de reporte 2026-06-30SEC · 2026-08-04 ↗
|
| NETCloudflareCloud network & securityCrecimiento comercial | Prioridad de investigación★★★☆☆3 / 5 | RiesgoAlto4 / 5 | Security and developer services can grow on a shared global network. Tesis, riesgos y fuentesQué debe salir bienExpand paid enterprise adoption while improving GAAP profitability. Qué rompería la tesisCompetition, service failures, network spending and share-based compensation. Antes de evaluar el precioReconcile adjusted profit with GAAP losses, cash flow and diluted shares. Escenario de retorno excepcional10× requires sustained adoption plus entry-multiple discipline. August 6, 2026 release reports revenue growth alongside a GAAP operating loss. Fuente de la empresa ↗ Datos de la empresa → |
$280.70Stored close · 2026-10-30-22.2%From 252-session closing peak
Cambio en 63 sesiones -0.7%Cambio en 252 sesiones +23.4%
Crecimiento de ingresos 35.9%Margen neto -8.2%ROE -12.7%Aceleración de EPS —Período de reporte 2026-06-30SEC · 2026-08-06 ↗
|
| CRWDCrowdStrikeCiberseguridadEmpresas de comparación | Prioridad de investigación★★★☆☆3 / 5 | RiesgoAlto4 / 5 | Security platform consolidation may increase recurring customer spending. Tesis, riesgos y fuentesQué debe salir bienSustain retention, cross-selling and reliable service delivery. Qué rompería la tesisService incidents, liability, competition and elevated valuation. Antes de evaluar el precioTrack recurring revenue, renewal concessions and free cash flow after dilution. Escenario de retorno excepcionalEstablished software comparison; no supported 10×/100× thesis. Company investor materials describe the Falcon cybersecurity platform. Fuente de la empresa ↗ Datos de la empresa → |
$241.81Stored close · 2026-11-02-13.3%From 252-session closing peak
Cambio en 63 sesiones +14.5%Cambio en 252 sesiones +79.6%
Crecimiento de ingresos —Margen neto —ROE 1.1%Aceleración de EPS —Período de reporte 2026-07-31SEC · 2026-08-27 ↗
|
| DDOGDatadogCloud observabilityCrecimiento comercial | Prioridad de investigación★★★☆☆3 / 5 | RiesgoAlto4 / 5 | More complex cloud and AI workloads require monitoring and security tools. Tesis, riesgos y fuentesQué debe salir bienExpand paid usage while maintaining retention and cash efficiency. Qué rompería la tesisCloud-spend optimization, competition and share-based compensation. Antes de evaluar el precioInspect consumption trends, customer concentration and per-share cash economics. Escenario de retorno excepcional10× depends on exceptional sustained growth and a reasonable entry price. Company publishes Q2 2026 results and materials on observability and security. Fuente de la empresa ↗ Datos de la empresa → |
$235.27Stored close · 2026-10-30-19.8%From 252-session closing peak
Cambio en 63 sesiones -14.0%Cambio en 252 sesiones +50.8%
Crecimiento de ingresos 35.6%Margen neto 4.5%ROE 4.1%Aceleración de EPS 985.7 ppPeríodo de reporte 2026-06-30SEC · 2026-08-06 ↗
|
| DUOLDuolingoDigital educationCrecimiento comercial | Prioridad de investigación★★★☆☆3 / 5 | RiesgoAlto4 / 5 | A broad learning audience can support paid subscriptions and additional courses. Tesis, riesgos y fuentesQué debe salir bienConvert engagement into retained paid users without excessive acquisition costs. Qué rompería la tesisAI competition, weaker monetization, churn and platform dependence. Antes de evaluar el precioCompare bookings, recognized revenue, paid retention and free cash flow. Escenario de retorno excepcional10× needs durable monetization, not just growth in free users. Company investor materials describe its learning platform and subscription business. Fuente de la empresa ↗ Datos de la empresa → |
$131.59Stored close · 2026-10-30-51.4%From 252-session closing peak
Cambio en 63 sesiones -3.1%Cambio en 252 sesiones -51.8%
Crecimiento de ingresos 18.3%Margen neto 35.9%ROE 29.1%Aceleración de EPS -51.1 ppPeríodo de reporte 2026-06-30SEC · 2026-08-06 ↗
|
| APPAppLovinAdvertising softwareCrecimiento comercial | Prioridad de investigación★★★☆☆3 / 5 | RiesgoExtremo5 / 5 | Better ad targeting and measurement can attract advertiser spending. Tesis, riesgos y fuentesQué debe salir bienDemonstrate repeat advertiser returns and diversify demand profitably. Qué rompería la tesisPlatform policy, privacy rules, advertiser concentration and valuation. Antes de evaluar el precioCheck organic sales, cash quality, leverage and dependence on external platforms. Escenario de retorno excepcional10× is an exceptional outcome; recent operating growth is not a return forecast. Company investor materials describe advertising software and its performance platform. Fuente de la empresa ↗ Datos de la empresa → |
$228.85Stored close · 2026-11-02-68.8%From 252-session closing peak
Cambio en 63 sesiones -45.5%Cambio en 252 sesiones -63.1%
Crecimiento de ingresos 52.8%Margen neto 64.6%ROE 139.4%Aceleración de EPS -55.9 ppPeríodo de reporte 2026-06-30SEC · 2026-08-05 ↗
|
| QBTSD-Wave QuantumQuantum computingTecnología de vanguardia | Prioridad de investigación★★☆☆☆2 / 5 | RiesgoExtremo5 / 5 | Quantum optimization and computing could find repeat commercial uses. Tesis, riesgos y fuentesQué debe salir bienTurn pilot activity into repeat orders and revenue that covers growing costs. Qué rompería la tesisLumpy system sales, limited commercial demand, cash burn and competing approaches. Antes de evaluar el precioValue recognized recurring demand separately from bookings and one-off system sales. Escenario de retorno excepcional10× remains a speculative adoption scenario; a technology headline is not proof. Q2 2026 financial results disclose operating investment and losses. Fuente de la empresa ↗ Datos de la empresa → |
$10.65Stored close · 2026-10-30-71.3%From 252-session closing peak
Cambio en 63 sesiones -46.7%Cambio en 252 sesiones -68.9%
Crecimiento de ingresos -0.6%Margen neto -2001.6%ROE -23.0%Aceleración de EPS —Período de reporte 2026-06-30SEC · 2026-08-06 ↗
|
| RGTIRigetti ComputingQuantum computingTecnología de vanguardia | Prioridad de investigación★★☆☆☆2 / 5 | RiesgoExtremo5 / 5 | Superconducting quantum processors may benefit if scalable useful systems emerge. Tesis, riesgos y fuentesQué debe salir bienDemonstrate reliable systems and convert technical milestones into paying demand. Qué rompería la tesisHardware roadmap misses, competing architectures, cash burn and dilution. Antes de evaluar el precioCheck system revenue, cash runway and financing needs before revenue multiples. Escenario de retorno excepcional10× is a tail outcome with technical and commercial failure risk. Investor overview describes the full-stack superconducting platform and Q2 2026 reporting. Fuente de la empresa ↗ Datos de la empresa → |
$11.25Stored close · 2026-10-30-74.6%From 252-session closing peak
Cambio en 63 sesiones -29.8%Cambio en 252 sesiones -71.5%
Crecimiento de ingresos —Margen neto —ROE -44.4%Aceleración de EPS —Período de reporte 2026-06-30SEC · 2026-08-06 ↗
|
| RXRXRecursionDrug discoveryTecnología de vanguardia | Prioridad de investigación★★☆☆☆2 / 5 | RiesgoExtremo5 / 5 | Computational discovery may produce valuable medicines and partnerships. Tesis, riesgos y fuentesQué debe salir bienPositive clinical evidence and meaningful partner milestones. Qué rompería la tesisTrial failure, regulatory setbacks, cash burn and dilution. Antes de evaluar el precioUse risk-adjusted clinical programs and cash runway, not a software revenue multiple. Escenario de retorno excepcionalBinary clinical outcomes make 10× scenarios highly uncertain; capital loss is possible. Company describes a clinical-stage pipeline and AI-enabled drug discovery platform. Fuente de la empresa ↗ Datos de la empresa → |
$4.03Stored close · 2026-10-30-28.7%From 252-session closing peak
Cambio en 63 sesiones +26.7%Cambio en 252 sesiones -31.3%
Crecimiento de ingresos -60.1%Margen neto -945.9%ROE -56.7%Aceleración de EPS —Período de reporte 2026-06-30SEC · 2026-08-05 ↗
|
| ENVXEnovixBattery technologyTecnología de vanguardia | Prioridad de investigación★★☆☆☆2 / 5 | RiesgoExtremo5 / 5 | Higher energy-density batteries may win demanding device applications. Tesis, riesgos y fuentesQué debe salir bienCustomer qualification, manufacturing yield and profitable volume production. Qué rompería la tesisProduction yield, delayed qualification, cash burn and funding needs. Antes de evaluar el precioModel yield, unit cost and funded capacity before extrapolating design wins. Escenario de retorno excepcional10× requires successful industrial scaling; prototype performance is insufficient. Company investor overview; manufacturing and qualification remain key diligence topics. Fuente de la empresa ↗ Datos de la empresa → |
$3.15Stored close · 2026-10-30-74.2%From 252-session closing peak
Cambio en 63 sesiones -25.4%Cambio en 252 sesiones -73.2%
Crecimiento de ingresos 20.8%Margen neto -473.9%ROE -81.0%Aceleración de EPS —Período de reporte 2026-07-05SEC · 2026-08-12 ↗
|
| LEUCentrus EnergyNuclear fuelTecnología de vanguardia | Prioridad de investigación★★☆☆☆2 / 5 | RiesgoExtremo5 / 5 | Domestic enrichment and advanced-reactor fuel may become important supply constraints. Tesis, riesgos y fuentesQué debe salir bienSecure funded demand and scale enrichment capacity at viable unit costs. Qué rompería la tesisPolicy dependence, supply restrictions, construction funding and timing of reactor demand. Antes de evaluar el precioSeparate existing fuel supply economics from still-to-be-funded enrichment expansion. Escenario de retorno excepcionalA speculative scaling scenario; funding and dilution can overwhelm operating progress. Company materials describe nuclear fuel supply, enrichment technology and HALEU capabilities. Fuente de la empresa ↗ Datos de la empresa → |
$103.29Stored close · 2026-10-30-73.1%From 252-session closing peak
Cambio en 63 sesiones -44.1%Cambio en 252 sesiones -73.6%
Crecimiento de ingresos 14.0%Margen neto 10.2%ROE 5.7%Aceleración de EPS 20.3 ppPeríodo de reporte 2026-06-30SEC · 2026-08-06 ↗
|
| QUBTQuantum Computing Inc.Quantum & photonicsTecnología de vanguardia | Prioridad de investigación★☆☆☆☆1 / 5 | RiesgoExtremo5 / 5 | Photonic products and foundry services may develop commercial demand. Tesis, riesgos y fuentesQué debe salir bienVerify repeat external orders, recognized revenue and production economics. Qué rompería la tesisUnproven commercial scale, execution, cash consumption and dilution. Antes de evaluar el precioRequire customer and revenue evidence before applying a sales multiple. Escenario de retorno excepcionalNo support for a 100× investment thesis; commercial evidence must come first. Company investor relations; valuation and sustained commercial scale require further diligence. Fuente de la empresa ↗ Datos de la empresa → |
$6.60Stored close · 2026-10-30-60.5%From 252-session closing peak
Cambio en 63 sesiones -24.5%Cambio en 252 sesiones -57.5%
Crecimiento de ingresos 9000.0%Margen neto -152.5%ROE -0.9%Aceleración de EPS —Período de reporte 2026-06-30SEC · 2026-08-10 ↗
|
Ninguna empresa coincide con estos filtros. Amplíe un umbral o elimine una condición.
SCENARIO LAB
Start with a dated market cap from a trusted source. These are your assumptions, not live company data. See how dilution and the future valuation multiple change the sales required for a share-price return.
Ingrese capitalización de mercado positiva, ingresos anuales y precio/ventas; el crecimiento de acciones debe ser 0–1000%. Entradas faltantes o inválidas no producen estimación.
Escenarios ilustrativos basados en sus entradas, no objetivos de precio
Future equity market cap = current cap × share-price multiple × (1 + new shares / current shares). Required annual sales = future equity cap / assumed equity price-to-sales. Revenue CAGR = (required sales / current annual sales)^(1 / years) − 1. The model excludes dividends, taxes and currency effects. It does not price bankruptcy risk or establish that a future sales multiple is reasonable. Clinical-stage biotechnology and banks need different valuation models.
Stars rank the order of further research for this particular 2–3 year brief. They are editorial assessments, not model scores, return forecasts or buy recommendations. The same rating is a tie; row order within it is not a finer ranking.
★★★★★ requires a verified attractive entry valuation and a complete thesis review; no company receives it here. ★★★★☆ prioritizes a visible commercial catalyst. ★★★☆☆ means material questions remain. ★★☆☆☆ needs technical, clinical or commercial milestones. ★☆☆☆☆ needs stronger revenue evidence before a return thesis. Reviews expire after 90 days.
Risk describes business and financing uncertainty on an editorial 1–5 scale. 3 is substantial, 4 high and 5 extreme. It is not a loss probability, and all rows carry valuation risk.
SEC facts and daily price history reuse the existing FinEdg data store. SEC snapshot as of 2026-11-04; page observed 2026-11-04 18:34 UTC. A covered issuer can still have missing metrics.
Revenue growth compares the latest supported quarter with a year earlier. Net margin uses four matched quarters. A missing value stays unavailable. A stored close must be no more than seven calendar days old; it is not a live quote. Price changes compare closes 63 or 252 stored sessions apart; they require 64 or 253 valid observations, respectively. They exclude dividends and are historical, not return forecasts. ROE uses trailing-four-quarter net income over current reported equity; EPS acceleration is the change in year-on-year EPS growth, in percentage points. Sorting is descending with missing observations last, and does not rank cheapness. The drawdown compares that close with the maximum of the last 252 stored daily closes, not total return or intrinsic value.
Price provenance: Daily EOD closes from the BibaMoney price store (splits reflected, cash dividends not).
Algoseek API access has been checked separately. Its feed is not the source of this public table; display rights and integration remain unconfirmed. No Algoseek observations are exposed here.
Not verified in this view. A 13F reports quarterly holdings, not a real-time trade tape. Purchases require comparison of share counts across matched filings, with amendments and corporate actions handled. Short positions are omitted. The Q2 2026 reporting deadline was August 14, 2026. SEC Form 13F guidance ↗
These 44 names are a curated research list, not a screen proving capitalization below $10bn. A lower stock price, a drawdown, or a smaller capitalization than a competitor does not establish a bargain.